Country differences in hospitalisation, length of stay and admission to Intensive Care Units due to SARS-CoV-2 infection: a rapid review of available literature

Elizabeth A Lane[1, 2], Damien J Barrett[2, 5], Miriam Casey[1] , Conor G. McAloon[3], Áine B. Collins[1, 2], Kevin Hunt[4] , Andrew W. Byrne[5], David Mc Evoy [6], Ann Barber [1], John Griffin[1], Patrick Wall[6] and Simon J. More[1]

[1] Centre for Veterinary Epidemiology and Risk Analysis, UCD School of Veterinary Medicine, University College Dublin, Belfield, Dublin D04 W6F6, Ireland;

[2] Department of Agriculture, Food and the Marine, Administration Building, Backweston Campus, Celbridge, Co. Kildare, Ireland;

[3] Section of Herd Health and Animal Husbandry, UCD School of Veterinary Medicine, University College Dublin, Dublin D04 W6F6, Ireland;

[4] School of Biosystems and Food Engineering, University College Dublin, Belfield, Dublin 4, Ireland;

[5] One Health Scientific Support Unit, Department of Agriculture, Food and the Marine, Kildare Street, Dublin 2;

[6] School of Public Health, Physiotherapy and Sports Science, University College Dublin, Belfield, Dublin 4, Ireland.

Running title: Country differences in hospitalisation and length of stay following SARS-CoV-2 infection

Corresponding author: Elizabeth A Lane

Tel: Int-353-01-5058706; Mobile: Int-353-87-2433849

Email: Elizabeth.lane@ucd.ie

Abstract

Objectives: Coronavirus disease (COVID-19) caused by the SARS-CoV-2 virus is spreading rapidly worldwise and threatening the collapse of national health care systems. The development of effective resource models are critical for long term health planning. The aim was to evaluate the available literature, to consider parameters affecting hospital resources, to effectively guide health policy and planning. **Design**: A detailed search of the literature, using Google Scholar, PubMED, MedRxiv and BioRxiv, was conducted for the time period 01-DEC-2019 to 04-MAY-2020; using appropriate keywords: resultant articles were scrutinised in detail, and appraised for reported data pertaining to hospitalization and hospital length of stay (LOS). **Results**: Disease presentation was described in China; 81 % mild, 14 % moderate and 5 % severe. The experience, thus far, in Europe and the USA are suggestive of a higher degree of severity. Initial reports suggest high hospitalisation and ICU admittance rates. More recent reports from the ECDC lower this estimation. Perhaps the relative age, the level of pre-existing conditions, and other health factors may be contributors to differences. Data from Irish cases suggest hospitalisation rate may be lower in parts of Europe and time dependent. Hospital LOS is described in seventeen articles, with median lengths of stay between 4 and 25 days. The evidence regarding the LOS in ICU is reported in eighteen studies, fifteen deemed relevant. The majority of studies report ICU LOS between 7 to 10 days. Many of these studies are likely skewed towards shorter stay due to study cut-off dates. Indications based on ICU LOS reported for patients continuing care suggest median ICU stay will be longer. **Conclusions**: These parameter estimates are key to the development of an effective health care resource model. Based on our rapid appraisal of the literature, is it essential that Europe manages mitigation measures to ensure that hospital and ICU capacity does not become overwhelmed to manage this pandemic long term.

Keywords: Hospitalisation, Length of Stay, Hospital stay, ICU, SARS-CoV-2, COVID-19

53

54 **Contents**

55 1. Introduction

56 2. Materials and methods

57 2.1 *Initial study appraisal*

58 *2.2 Study appraisal*

59 *2.3 Data sources and management*

60 3. Results

61 3.1 Hospitalisation rate

62 3.2 Length of stay (LOS)

63 *3.2.1 Length of stay in hospital (non-ICU)*

64 *3.2.2 Length of stay in ICU*

65 *3.2.3 Length of stay pre transfer to ICU*

66 *3.2.4 Length of stay post ICU*

67 *4.* Discussion

68 4.1 Hospitalisation rate

69 4.2 Length of stay (LOS)

70 5. Limitations of this rapid review

71 6. Conclusions

72 7. Conflict of interest statement

73 8. Funding

74 9. References

75

76

77

78

1. INTRODUCTION

Coronavirus disease (COVID-19) caused by the SARS-CoV-2 virus is spreading rapidly across the world, threatening the collapse of many national health care systems and exerting a grave impact on the global economy. As of 9th May 2020, data compiled from the European Centre for Disease Prevention and Control (ECDC) reported 3,898,658 confirmed infections of COVID-19 cases worldwide with 274,290 deaths recorded. The SARS-CoV-2 virus, first detected in December 2019, in Wuhan China, has spread to 212 countries and territories. By 9th May 2020, European countries, including the European Union (EU)-27, the UK, Norway, Switzerland and Iceland have reported 1,259,681 cases and 147,085 deaths following infection with SARS-CoV-2 infection (ECDC, 2020).

Clinical presentations of COVID-19 range from asymptomatic to life threatening and fatal (World Health Organisation (WHO), 2020); Wu and McGoogan (2020) outlined the spectrum of disease of COVID-19 in China; 81 % were mild; 14 % severe and 5 % critical. The experience in European countries has differed, and varied among countries. The eight update Report from the ECDC (2020a) indicates that up to 30 % of diagnosed COVID-19 cases were hospitalised in some countries. Individual studies from Italy (Cereda et al., 2020; Grasselli et al., 2020) indicated a higher proprotion were accessing ICU care, with 16 and 18 % of all COVID-19 patients being cared for in an ICU setting. However, the European wide analysis report (ECDC, 2020a) suggests severe illness requiring respiratory support or ICU care has accounted for 2.4 % cases, the most recent report; the ninth update (ECDC, 2020b) lowers this esimtate (median 2 %).

Worldwide, age and co-morbidities have been demonstrated as major risk factors for the development of severe disease (Chen et al., 2020; ECDC, 2020a; 2020b; COVID-19 Surveillance Group , 2020; Gang et al., 2020; Paranjpe et al., 2020; Qian et al., 2020;

Richardson et al., 2020; Russell et al., 2020; Wu and McGoogan, 2020). Children are implicated as possible asymptomatic carriers of SARS-CoV-2 virus and a number of articles report both symptomatic and asymptomatic infection in children (Chan et al., 2020; Hu et al., 2020; Korean Society of Infectious Diseases et al., 2020; Liao et al., 2020; Qiu et al., 2020; Tao et al., 2020; Wu and McGoogan 2020). Many, but not all (Korean Society of Infectious Diseases 2020), studies indicate a higher proportion of cases are male (Chen et al., 2020; ECDC, 2020a; 2020b; Fan et al., 2020; Linton et al., 2020; COVID-19 Surveillance Group, 2020; ICNARC, 2020a; 2020b); and recent risk assessments conducted by the ECDC (ECDC, 2020a; 2020b) indicates that males are at higher risk of death compared with their female contempories. Close contact with a case is a risk factor (WHO, 2020), and the basis of public health advice includes social distancing and staying at home apart from essential activity (ECDC, 2020a). Bi et al. (2020) reports that household contacts (Odds Ratio 6) and those travelling with a case were at higher risk of infection (OR 7) than other close contacts. Other factors, including smoking (Vardavas and Nikitara, 2020) have been highlighted as risk factors for severe infection. There are indications too that infection rate may be altered by blood-group (Fan et al., 2020; Zhao et al., 2020).

The prevention of infection among health care workers is of critical importance to the management of this pandemic. Of serious concern to policymakers is the clear evidence indicating that both healthcare workers and hospitalised persons are at particularly high risk of exposure (WHO 2020; Istituto Superiore di Sanità 2020). Indeed some of the work conducted early in the epidemic reported hospital-associated transmission of virus was suspected in 41% of patients (Wang et al., 2020; n= 138). Of concern too, many healthcare authorities are bringing retired medics and nurses back into service. The placement of these people considered vulnerable due to their age must be considered. At a national level, the

latest work by Stier et al. (2020) emphasizes population density, with attack rates increasing with city size.

Preparedness is key and resource matching to clinical requirement essential. Previous work (Rhodes et al., 2012) suggests a large variation in availability of critical care bed in the EU / EEA area, ranging from 29.2 in Germany to 4.2 critical care beds per 100,000 population in Portugal. Perhaps this is key to understanding the difference in coping between different EU countries. Clearly too, differences will exist between cultures, few western governments will seek to use hospitalisation as a tool for quarantine. As the infection is spreading across the world; this rapid review paper considers parameters affecting hospital resources resulting from infection with SARS-CoV-2 beyond the evidence published from China. The objective is to evaluate the current scientific literature from across the developed world with the overall aim to influence health policy and support evidence-based decision-making. The proportion of patients hospitalized due to infection with SARS-CoV-2 infection is discussed. The proportion of patients who required critical or ICU care is outlined. Time spent hospitalised; both in a general and an ICU setting is considered. For those who have been admitted to an ICU, the length of time pre ICU, the length of time in ICU and the length of time post ICU to discharge or death was collated from available literature. These estimates are central to national resource modelling, which are being developed to aid policymakers to ensure optimal resourcing during this pandemic.

2. MATERIALS AND METHODS

2.1 Initial study appraisal

This paper follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses—Extension for Scoping Reviews (PRISMA-ScR) checklist (Tricco et al., 2018). A comprehensive search of the scientific literature and national and international government

156 reports was conducted by contributing researchers for the time period 1st December 2019 to
157 4th May 2020. The search engines Google Scholar, PubMED, MedRxiv and BioRxiv were used,
158 using the following keywords: ("Novel coronavirus" OR "SARS-CoV-2" OR "2019-nCoV" OR
159 "COVID-19") AND ("length of stay" OR "duration of stay" OR "hospital stay" OR "ICU"). No
160 restriction on language was imposed as long as the abstract was available in English.
161 References within these publications were also searched as additional possibilities for
162 inclusion. Inclusion criteria for 'the proportion of cases hospitalised' were papers that
163 reported the proportion of hospitalised and proportion of those hospitalised accessing
164 higher level care including critical care and intensive care unit (ICU) care. Inclusion criteria
165 for 'length of stay' (LOS) included articles that reported length of hospital stay, length of stay
166 in ICU, length of stay prior to admission to ICU, and articles that referenced length of stay
167 post discharge from ICU to a general hospital setting. Each article was assessed briefly for
168 suitability for inclusion in this study. Papers that did not report length or duration of time in
169 hospital or in ICU were discarded. The latest governmental reports from the Health
170 Protection Surveillance Centre (HPSC), Ireland, and from the Intensive Care National Audit
171 and Research Centre (ICNARC, 2020a), UK were consulted after the 4th May cut-off.
172
173 *2.2 Study appraisal*
174 All articles and reports that described the proportion of COVID-19 positive cases
175 hospitalised, the proportion of cases that were admitted to higher level care including
176 critical or ICU care, the length of hospital stay or the duration of hospital stay or length of
177 time in critical care or ICU were scrutinised in detail, and appraised for reported data and
178 quality of the scientific evidence. Parameter estimates for the length of stay in non-ICU or in
179 an ICU setting from the relevant articles were recorded and evaluated.
180

181 For quality control, studies were (1) selected from search terms outlined above and initially
182 screened by three members of the team (*KH, SM and LL*), with parameters identified and
183 recorded; (*2*) reviewed and supplemented by manual search by *LL*, again with parameters
184 identified and recorded. (*iii*) Finally, the review was then internally reviewed by an additional
185 three members of the team (*SM, DB, MC*), and cross-referenced with other parameter
186 synthesis documents being developed by the group (*all authors*). Details of the resultant list
187 (n = 179), which included published and pre-printed articles, were entered in an Excel file.
188
189 Eighteen studies relating to hospital LOS and fifteen studies or reports relating to LOS in ICU
190 were selected for detailed scrutiny as they each reported summary estimates with a
191 corresponding variance. The Italian report (COVID-19 Surveillance Group, 2020) was the only
192 report without an estimate of variance that was considered for detailed scrutiny, as the
193 study population was significant (n = 25,452).
194
195 2.3 Source data and management
196 Data tabulating the daily number of notified cases and deaths for all countries and
197 Territories worldwide was downloaded in Excel format from the European Centre for
198 Disease Prevention and Control (ECDC) and may be accessed at:
199 https://www.ecdc.europa.eu/en/publications-data/download-todays-data-geographic-
200 distribution-covid-19-cases-worldwide. Data was imported into STATA version 14 (STATA
201 Corporation, USA). Cumulative cases and deaths were generated for each calendar day for
202 countries of interest, and expressed as a percentage of cumulative deaths to cumulative
203 cases. The crude mortality rate was expressed as a percentage over time, from day of
204 outbreak, defined as the day on which the tenth case was reported, in selected European
205 Countries.
206

207 Data regarding the epidemiological situation in Ireland was extracted from the Health
208 Protection Surveillance Centre daily epidemiological reports. These may be accessed a:
209 https://www.hpsc.ie/a-
210 z/respiratory/coronavirus/novelcoronavirus/casesinireland/epidemiologyofcovid-
211 19inireland/. Data were entered into Excel, then imported into STATA 14 to generate the
212 trends in cumulative cases, percentage of known cases hospitalised and the percentage of
213 confirmed cases admittance into ICU over time.
214
215 **3. RESULTS**
216 **3.1 HOSPITALISATION RATE**
217 A summary of available scientific literature from the outbreaks worldwide relating to the
218 proportion of COVID-19 cases requiring hospitalisation and the need for stepped up medical
219 care, including critical care and ICU, by country, is presented in Table 1. Data from 33 studies
220 or reports are presented.
221
222 << Insert Table 1 here >>
223
224 *European Centre for Disease Prevention and Control (ECDC updates)*
225 The European Centre for Disease Prevention and Control (ECDC) collates the laboratory-
226 confirmed cases reported to the European Surveillance System (TESSy) and thus far has
227 published nine update reports as the situation unfolds across Europe (ECDC, 2020a; 2020b).
228 Preliminary estimates of severity were collated based on the analysis of data from EU and
229 EEA countries and from the UK. As expected some data were incomplete or missing in TESSy.
230 The eight update (ECDC, 2020a) indicates that 48,755 of 152,375 (32 %) were hospitalised
231 based on data from 26 European countries; with a country median 28 % (IQR 14 to 63 %).
232 Severe presentations that required ICU and or respiratory support accounted for 2,859 of

233 120,788 (2.4 %) cases from 16 countries; median 1.4 % (IQR 0 to 33 %). Among hospitalized
234 cases only, severe illness was reported in 3,567 of 38,960 (9.2 %) cases from 19 countries,
235 median 15 % (IQR 3.8 to 35 %). Death occurred in 1,005 of 9,368 (11 %) of hospitalized cases
236 from 21 countries (3.9 %, IQR 0 to 13 %). Age-specific risk increased among those 60 years
237 and older, thus consideration to age profile within a country is important. The latest report
238 on 23rd April reported increased rate of hospitalisation with a pooled estimate of 42 %
239 (160,485 of 381,410 cases); based on data from 19 countries, however the country median
240 was 28 % (IQR 16 to 39 %). Severe presentations that required ICU and or respiratory
241 support accounted for 5,456 of 220,412 (2 %) cases with data from 14 countries; median 2 %
242 (IQR 0 to 4 %). Again, hospitalisation increased with age, and for males from 30 years. The
243 changes over time in the crude mortality rate for all notified cases since day of outbreak,
244 defined as the day on which the tenth case was notified, for selected European countries is
245 presented in Figure 1.
246
247 << Insert Figure 1 here >>
248
249 *USA Studies*
250 Admission rates to ICU in the USA varied between 4.9 to 11.5 % (CDC COVID-19 Response
251 Team, 2020) report. Myers et al. (2020) indicated 8.7 % ICU admission in a study conducted
252 in California in March. While Lewnard et al., (2020) observed a higher ICU admission rate
253 (25.6 %) also in California. A number of studies conducted in New York outlined ICU
254 admission rates of 14.2 % (Richards et al., 2020); 22 % (Cummings et al., 2020); 23.6 %
255 (Argenizano et al., 2020); and 36% (Paranjpe et al., 2020). Of significance, are the mortality
256 rates in hospitalised groups (and specifically not ICU only groups) reported in a number of US
257 studies: 15.4 % Lewnard et al., (2020); 15.6 % Myers et al., 2020; 21 %; Richards et al., 2020;
258 21 %; Argenziano et al., 2020; and 29 % Paranjpe et al 2020.

In Ireland, the proportion of COVID-19 test positives cases (confirmed cases) hospitalised is reducing with time (Figure 2). Daily epidemiology reports compiled by the Health Protection Surveillance Centre (HPSC, 2020a) with data to March 30th reports a hospitalisation rate of 27.9 % (834 of 2,990 cases hospitalised) and admission to ICU in 4.2 % of cases (126 of 2,990). The hospitalisation rate reduced over time to 17.5 % (1,968 of 11,261) by April 13th (HPSC, 2020b); 13.5 % (2,669 of 9,723) by 29nd April (HPSC, 2020c); and 13.1 (2,878 of 21,908 cases by 4th May (HPSC, 2020d). The rate of admission to ICU reduced, concomitantly, from 4.2 % of cases (126 of 2,990; HPSC 2020a) to 1.7 % (373 of 21,908; HPSC 2020d) of cases by May 4th. The reports collated by the HPSC (HPSC Epi Team, 2020) in Ireland indicate that proportion of hospitalisations and transfer to ICU increased occurred with age.

<< Insert Figure 2 here >>

3.2 LENGTH OF STAY (LOS)

3.2.1 Length of stay in hospital (Non-ICU)

A summary of the literature pertaining to length of hospital stay in non-ICU settings due to COVID-19, by country, is reported in Table 2. The overall length of hospital stay is reported in eighteen studies or reports, with overall median lengths of stay between four days and twenty-five days. Figure 3 illustrates the median (and IQR) ranges of hospital length of stay for relevant articles.

<< Insert Table 2 here >>

<< Insert Figure 3 here >>

285 *3.2.2 Length of stay in ICU*

286 The literature pertaining to length of ICU stay due to COVID-19 is reported in Table 3,
287 including eighteen studies and reports. Figure 4 illustrates the median (and IQR) ranges of
288 length of stay in ICU for relevant articles. In this figure, fifteen studies are presented; Three
289 case studies were excluded due to small numbers of relevant cases (Chen et al., 2020;
290 Kujawski et al., 2020; Young et al., 2020). Median lengths of stay in ICU between 7 to 10 days
291 were observed in studies based in China (Cao et al., 2020; Fan et al., 2020; Yang et al.,
292 20202; Zhou et al., 2020). European studies conducted by Graselli et al. (2020) in Italy, Ceruti
293 et al (2020) in Switzerland, and the ICNARC report (2020a) report similar LOS between 7 to
294 10 days. Earlier reports from the ICNARC (2020b) indicated shorter LOS for ICU patients,
295 indicating the bias towards shorter stay as fewer patients had progress through their
296 complete stay. However median LOS outlined by studies based in North America were more
297 variable and reported lengths of stay between 3.5 to 23 days for various groups (Figure 3).
298
299 << Insert Figure 4 here >>
300
301 << Insert Table 3 here >>
302
303 *3.2.3 Length of hospital stay prior to transfer to ICU*

304 Length of hospital stay prior to transfer to ICU due to COVID-19, by country, is presented in
305 Table 4. Four studies made reference to time in hospital prior to ICU transfer, including two
306 small case series (Young et al., 2020; Kujawski et al., 2020). A long median hospital stay prior
307 to transfer to ICU was described by Fan et al. (2020; median 8 days, IQR 4 to 11 days). The
308 UK ICNARC report (ICNARC 2020a) details a median length of stay of one day (IQR 0 to 3
309 days); indicating the short duration before stepped up care need is identified in COVID-19
310 patients.

<< Insert Table 4 here >>

3.2.4 Length of hospital post ICU

No eligible studies outlining the length of stay post discharge from ICU were discovered.

4. DISCUSSION

4.1 HOSPITALISATION RATE

The relative variation in disease severity is very clear in the published literature from China; 81 % mild presentation, 14 % moderate presentation with 5 % severe or critical presentations that require high-level on-going care in critical care beds or within the ICU environment (Wu and Grogan, 2020). Nevertheless, the experience, thus far, in Europe and the USA would suggest some countries are experiencing a higher degree of severity of COVID-19 being reported. Early indications from Italy suggested hospitalisation rates of 30 % and admission to ICU between 16 to 18 % (Cereda et al., 2020; Graselli et al., 2020). While the eight update report from the ECDC (ECDC 2020a) restates this but suggests based on data from 16 EU countries that respiratory and or ICU support is needed in 2.4 % of cases; the latest ECDC report (ninth Update; ECDC 2020b) revises this slightly country specific median 2 % (IQR 0 to 4 %). Studies conducted in the USA too report high rates of hospitalisation (CDC COVID-19 Response Team, 2020), high proportion of patients admitted to ICU care and very high mortality rates (Argenziano et al, 2020; Cummings et al., 2020; Lewnard et al., 2020; Myers et al., 2020; Paranjpe et al., 2020). The cause of the differences in disease presentation between countries is not clear. Perhaps differences in case definition, the relative age of the population, the level of pre-existing conditions within the

337 population, and other health factors may be contributing to these differences. Given the
338 experience in Italy, thus far, suggests that must carefully manage mitigation measures to
339 ensure ICU capacity is not reached or breached. However, another major influencer on
340 hospitalisation rate will be the definition of a suspect case and the extent of COVID-19
341 testing within the community; the detection of a greater number of milder cases, diagnosed
342 within the community will ultimately influence the hospitalisation rate. The influence of
343 community testing is becoming evident in Ireland; as April progresses, it is clear in each
344 subsequent HPSC report (2020a; 2020b; 2020c; 2020d) that the rate of hospitalisation and
345 proportion of patients admitted to ICU is reducing. This is evidence perhaps that a broader
346 case suspect definition and a wider testing approach will impact the overall rate of
347 hospitalisation and admission to ICU.
348
349 **4.2 LENGTH OF STAY (LOS)**
350 *4.2.1 Length of stay in hospital (Non-ICU)*
351 The overall length of hospital stay varied between 4 and 25 days among studies; two of
352 these studies were case series based on the observations of 10 (Lo et al., 2020) or 12
353 (Kujawski et al., 2020) patients, a further article (Linton et al., 2020) was based on data
354 extracted from publically available datasets. The studies are very diverse in their reporting
355 and presentation of hospital length data. The largest study is an Italian report (Instituto
356 Superiore di Sanità, 2020) reporting the median hospital stay of 5 days for cases that did not
357 require ICU level of care. However, no range or confidence interval is described by this
358 report. Similar to the shorter duration of hospital stay in Italy, a more recent study
359 conducted in the USA, which examined hospital records of 5,700 sequential admissions to
360 New York hospitals, reported a short length of stay, median 4.1 days (IQR 2.3 to 6.8). The
361 hospital length of stay varies dramatically among different studies. Perhaps differences in
362 hospital capacity, overcrowding, government policy, funding source and other factors might

363 influence length of stay. Of interest Richardson et al. (2020) indicates 45 patients were re-
364 admitted to hospital for further care, indicating perhaps the pressure on bed availability.
365 Argenziano et al. (2020) outlines the critical situation faced in some Emergency Departments
366 in New York and describes the death of 14.7 % of ED only patients; patients who died in the
367 emergency room prior to being admitted to hospital. Given the large variation in length of
368 stay and the difference between continents; the studies relating to hospital LOS outside an
369 ICU setting were not appropriate to use to calculate a central tendency.
370
371 *4.2.2 Length of stay in hospital (ICU)*
372 Studies from China (Cao et al., 2020; Fan et al., 2020; Yang et al., 2020; Zhou et al., 2020)
373 report median ICU stays of 7 to 10 days. Similar median lengths of stay have been reported
374 in Italy. The Italian report (COVID-19 Surveillance Group, 2020) dated 29th April 2020
375 describes median LOS of 8 days if admitted to an ICU setting (n = 25,452); however, actual
376 length of time in ICU and proportion or number of patients cared for in ICU were not
377 specified. Important too, to note, this report while including a large number of cases, only
378 includes those who have died, and hence will not reflect the possible longer stay of
379 survivors. Another Italian study conducted by Grasselli et al. (2020b) reports the median
380 length of ICU stay was 9 days (IQR 6 to 13 days) for 1,581 patients. A Swiss study, too,
381 outlined the median length of stay was 9 days for 41 patients followed to discharge (Ceruti
382 et al., 2020). It is noticeable that length of ICU stay is more variable in US studies. In
383 particular studies that breakdown length of stay into those completed stay compared to
384 patients continuing care. It is evident that care must be taken with interpretation, continuing
385 care groups are reported to have longer stays; median LOS of 11.4 (Petrilli et al., 2020); 14
386 (Bhatraju et al., 2020); and 23 days (Argenziano et al., 2020) are outlined. A smaller case
387 series conducted by Valente-Acosta in Mexico highlights this continuing care group; this
388 study describes a case series of 33 patients admitted to ICU in Mexico city, the median LOS

389 of 23 days is indicative that LOS in ICU can be significant; although their continuing care
390 group is only n = 4. The authors of the UK ICNARC (2020a) report clearly highlight the
391 influence of bias towards shorter stay; with both survivor and non-survivor groups reported
392 to have a median LOS of 8 days (ICNARC, 2020a). Indeed earlier reports from INCARC
393 (2020b) reported shorter LOS of ICU patients, as fewer persons had progressed through to
394 completion of treatment. It is evident that study cutoff, and short follow ups, have
395 influenced reported ICU LOS; it is clear that the influence of continuing care groups will
396 lengthen length of ICU stay somewhat in time.
397
398 *4.2.4 Length of hospital stay prior to transfer to ICU*
399 A long hospital stay (median 8 days, IQR 4 to 11 days) was reported by Fan et al., (2020) prior
400 to transfer to ICU, some of whom were diagnosed based on clinical findings. Given the
401 timing of the study so early in the outbreak and the lack of consistency regarding the
402 diagnosis, these data should be discounted when considering future resources. Only the UK
403 ICNARC report (2020a) details useful data pertaining to length of hospital in Europe. Median
404 length of hospital stay pre admission to ICU for laboratory confirmed COVID-19 patients (n =
405 8,233) was 1 day (IQR 0 to 3 days), indicating the short duration before stepped up care
406 need is identified in COVID-19 patients.
407
408 Length of stay post ICU is illustrated in a figure in some small case series; and as such, were
409 data were not extracted for reporting or discussion in this review.
410
411 **5. STUDY LIMITATIONS**
412 Limitations associated with any rapid review are pertinent to this study. A narrow aim was
413 set, namely to determine rate of hospitalisation and the length of stay in hospital due to
414 COVID-19 infection in countries across the world now at the centre of the pandemic. The

415 sources of the literature may be limited by the time-limited constraint of gathering relevant
416 literature (less than five weeks). However, this rapid approach was necessary, given the aim
417 was to provide evidence-based estimates of length of hospital stay to steer policy and
418 provide parameter estimates for utilisation within a hospital resource model. Inclusion of
419 articles in this review was assessed based on the subject being reported in the article and if
420 the numbers of cases were considered relevant. Another shortcoming was some of the
421 available literature is in pre-print form and only undergoing peer review.
422
423 **6. CONCLUSIONS**
424 Differences in the severity of case presentations have been described between continents;
425 and Ireland should base its expectation on those cases observed in Europe thus far in the
426 pandemic. Advice from the ECDC suggests hospitalisation rates of up to 42 % can be
427 expected. Additionally, we must expect increased level of care requirements, to critical care
428 and ICU levels, in up to 3 % of cases to allow for spare capacity, as mitigation measures are
429 relaxed in our jurisdiction. There is no doubt that the case definition in use and the
430 availability of community testing will determine the hospitalisation rate within a country. In
431 countries where community testing has been significant, we can expect the rate of
432 hospitalisation and the proportion requiring ICU level care to be lower. Preliminary data in
433 Ireland certainly supports this assertion.
434
435 The length of stay in hospital outside of the ICU setting, due to COVID-19 is highly variable in
436 the literature, with median estimates varying from 4 to 25 days. Studies diverged in their
437 inclusion criterion. It is likely that the aim of hospitalisation varied among countries.
438 Discharge criteria is divergent in different jurisdictions, whether it related to a patient
439 required to test negative prior to discharge or where there was pressure to free up

overcrowded hospitals. Indeed it is likely that some countries used hospitalisation to ensure quarantine.

As the pandemic spreads rapidly throughout the world, more and more evidence regarding the length of stay in ICU following COVID-19 is reported. Many of these reports indicate a median ICU length of stay between 7 to 10 days; however a number of these studies report length of stay based only on resolved cases, and as such duration of stay it is likely skewed towards a short stay due to bias towards those who have completed their ICU stay and are now discharged or have died. Thus the upper estimates of the range should be considered for use in resource models. It is apparent too that the data generated by each individual country during the initial months of the outbreak will be critical to estimate the parameters used for any national resource model.

Word count 4400

7. CONFLICT OF INTEREST STATEMENT

The authors do not have a financial or personal relationship with other people or organisations that could inappropriately influence or bias the content of the paper.

8. FUNDING

All authors were employed through their home institutions. No additional funding was used.

9. REFERENCES

466 Argenziano MG, Bruce SL, Slater CL, Tiao JR, Baldwin MR Barr RG, Chang BP, Chau KH, Choi
467 JJ, Gavin N, Goyal P, Mills AM, Patel AA, Romney M-LS, Safford MM, Kuiper JJ, Schluger
468 NW, Sengupta S, Sobieszczyk ME, Zucker JE, Asadourian PA, Bell FM, Boyd R, Cohen MF,
469 MacAlistair I, Colville LA, de Jonge JA, Dershowitz LB, Dey SA, Eiseman KA, Girvin ZP,
470 Goni DT, Harb AA, Herzik N, Householder S, Karaaslan LE, Lee H, Lieberman E, Ling A, Lu
471 R, Shou AY, Sisti AC, Snow ZE, Sperring CP, Xiong Y, Zhou HW, Natarajan K Hripcsak G,
472 Chen R. 2020. Characterization and clinical course of 1000 patients with COVID-19 in
473 New York: retrospective case series. MedRxiv preprint.
474 **doi:** https://doi.org/10.1101/2020.04.20.20072116
475 Badawi O, Liu X, Berman I, Amelung PJ, Doerfler M, Chandra S. 2020. Impact of COVID-19
476 pandemic on severity of illness and resources required during intensive care in the greater New
477 York City area. **doi:** https://doi.org/10.1101/2020.04.08.20058180. PrePrint
478 Barrasa H, Rello J, Tejda S, Martin A, Balzikueta G, Vinuesa C, Ferandez Miret B, Villagra A,
479 San Sebastian A, Cabenes S, Iribarren S, Fonseca F, Maynar J, and the Alana COVID19
480 Study Investigtors. 2020. SARS-Cov-2 in Spanish Intensive Care: Early Experience with
481 15-day Survival In Vitoria. Anaes Crit Care Pain Med. ePUB ahead of print. doi:
482 10.1016/j.accpm.2020.04.001
483 Bhatraju PK, Ghassemieh BJ, Nickols M, Kim R, Jerome KR, Nalla AK, Greninger AL, Pipavath
484 S, Wurfel MM, Evans L, Kritek PA, West TE, Luk A, Gerbino A, Dale CR, Goldman JD,
485 O'Mahony S, Mikacenic C. 2020. Covid-19 in Critically Ill Patients in the Seattle Region —
486 Case Series. NEJM DOI: 10.1056/NEJMoa2004500
487 Bi et al., Epidemiology and Transmission of COVID-19 in Shenzhen China: Analysis of 391
488 cases and 1,286 of their close contacts. https://doi.org/10.1101/2020.03.03.20028423
489 Borobia AM, Carcas AJ, Arnalich F, Alvarez-Sale R, Montserrat J, Quintana M, Figueira JC,
490 Santos Olmo RMT, Garcia-Rodriguez J, Martin-Vega A, Ramirez E, Buno A, Martinez-Ales
491 G, Garcia-Arenzana, Lopez CN, de Garcia MM, Moreno F, Reinisco-Barbero F, Martin-

492 Quiros A, River A, Mingorance J, Carpio CC, Arribas DP, Cuevas ER, Prados MC, Rios JJ,
493 Herman J, Arribas JR, COVID@HULP working team. 2020. A cohort of patients with
494 COVID-19 in a major teaching hospital in Europe.
495 **doi:** https://doi.org/10.1101/2020.04.29.20080853
496 Buerhaus PI, Auerbach DI, Staiger DO. Older Clinicians and the Surge in Novel Coronavirus
497 Disease 2019 (COVID-19). *JAMA.* Published online March 30, 2020.
498 doi:10.1001/jama.2020.4978.
499 Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen
500 N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F,
501 Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou
502 X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C,
503 Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden
504 FG, Horby PW, Zhang D, Wang C. 2020. A Trial of Lopinavir-Ritonavir in Adults
505 Hospitalized with Severe Covid-19. The New England Journal of Medicine.
506 doi:10.1056/NEJMoa2001282.
507 CDC COVID-19 Response Team 2020. Severe Outcomes among patients with Coronavirus
508 2019 (COVID-19)- United States, Feb 12 to March 16, 2020. MMWR Morb Mortal Wkly
509 Rep 69, 343-346.
510 Cecconi M, Pesenti A, of the COVID-19 Lombardy ICU Network 2020b. Baseline
511 Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to
512 ICUs of the Lombardy Region, Italy JAMA doi:10.1001/jama.2020.5394.
513 Chan JF-W, Yuan S Kok K-H, To K, Chu H, Yang J, Xing F, Liu J, Yip CC-Y, Pooon R, Tsoi H-W, Lo
514 SK-F Chan K-H, Poon VK-M, Chan W-M, Ip JD, Cai J-P, Cheng CC-C, Hui CK-M, Yuen K-Y. A
515 familial cluster of pneumonia associated with the 2019 novel coronavirus indicating
516 person-to-person transmission: a study of a family cluster Lancet 395: 514-523.

517 Chen N, Zhou M, Dong X, Ou J, Gong Y, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Z J Yu T, Chang X,
518 Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel
519 coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13.
520 Cereda D, Tirani M, Rovida F, Demicheli V, Ajelli M, Poletti P, Trentini F, Guzzetta G,
521 Marziano V, Barone A, Magoni M, Deandrea S, Diurno G, Lombardo M, Faccini M, Pan A,
522 Bruno R, Pariani E, Grasselli G, Piatti A, Gramegna M, Baldanti F, Melegaro A, Merler S.
523 2020. The early phase of the COVID-19 outbreak in Lombardy, Italy PrePrint
524 COVID-19 Surveillance Group (2020). Istituto Superiore di Sanità. Sorveglianza Integrata.
525 Characteristics of SARS-CoV-2 patients dying in Italy. Report based on available data on
526 April 13th, 2020. Accessed 15APR2020.
527 https://www.epicentro.iss.it/en/coronavirus/bollettino/Report-COVID-
528 2019_13_April_2020.pdf
529 Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Claasen J, Rabbani LE, Hastie J, Hochman BR,
530 Salazar-Schicchi J, Yip NH, Brodie D, O'Donnell MR. Epidemiology, clinical course, and outcomes
531 of critically ill adults with COVID-19 in New York City: a prospective cohort study
532 **doi:** https://doi.org/10.1101/2020.04.15.20067157 PrePrint
533 D'Adamo H, Yoshilkawa T, Ouslander JG. Coronavirus Disease 2019 in Geriatrics and Long-
534 term Care: The ABCDs of COVID-19 J Am Geriatr Soc. 2020 Mar 25. doi:
535 10.1111/jgs.16445. [Epub ahead of print]
536 European Centre for Disease Prevention and Control 2020a. Coronavirus disease 2019
537 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK – eighth
538 update, 8th April 2020. Stockholm. Accessed at:
539 https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-rapid-risk-
540 assessment-coronavirus-disease-2019-eighth-update-8-april-2020.pdf
541 European Centre for Disease Prevention and Control 2020b. Coronavirus disease 2019
542 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK – ninth update,

543 23rd April 2020. Stockholm. Accessed at:
544 https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-rapid-risk-
545 assessment-coronavirus-disease-2019-ninth-update-23-april-2020.pdf
546 Fan H, Zhang L, Huang B,Zhu M, Zhou Y, Zhang H, Tao X, Cheng S, Yu W, Zhu L, Chen J. 2020
547 Retrospective Analysis of Clinical Features in 101 Death Cases with COVID-19, MedRxiv
548 PrePrint https://doi.org/10.1101/2020.03.09.20033068
549 Garg S, Kim L, Whitaker M, O'Halloran A,Cummings C, Holstein R, Prill M, Chai SJ, Kirley PD,
550 Alden NB, Kawasaki B, Yousey-Hindes K, Niccolai L, Anderson EJ, Openo KP, Weigel A,
551 Monroe ML, Ryan P, Henerson J, Kim S, Como-Sabetti K, Lynfield R, Sosin D, Rores S,
552 Muse A, Bennett NM, Billing L, Sutton M, West N, Schaffner W, Talbot HK, Aquino C,
553 George A, Budd A, Brammer L, Lagley G, Hall AJ, Fry A. 2020. Hospitalization Rates and
554 Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease
555 2019 — COVID-NET, 14 States, March 1–30, 2020. Morbidity and Mortality Weekly
556 Report 69.
557 Guan WJ, Ni ZY, Hu Y, et al; China Medical Treatment Expert Group for Covid-19. Clinical
558 characteristics of coronavirus disease 2019 in China. *N Engl J Med*.
559 doi:10.1056/NEJMoa2002032 – Original research
560 Grasselli G, Presenti A, Cecconi M. 2020a Critical care Utilization for the COVID 19 outbreak
561 in Lombardy Italy. JAMA Opinion. Accessed at: https://jamanetwork.com/ by a NUS
562 Libraries User on 03/16/2020
563 Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini Luca, Castelli A, Cereda D, Coluccello
564 A, Foti G, Fumagalli R, Iotti G, Latronico N, Lorini L, Merler S, Natalini G, Piatti A, Ranieri
565 MV, Scandroglio AM, Storti E, Cecconni M, Pesenti A, COVID-19 ICU Network. 2020.
566 Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2
567 Admitted to ICUs of the Lombardy Region, Italy J*AMA.* Published online April 6, 2020b.
568 doi:10.1001/jama.2020.5394

569 HPSC Epi Team. 2020. Daily Epidemiology Reports compiled by the PSC are available at:
570 https://www.hpsc.ie/a-
571 z/respiratory/coronavirus/novelcoronavirus/casesinireland/epidemiologyofcovid-
572 19inireland/
573 HPSC. 2020a. Epidemiology of COVID-19 in Ireland. 1st April 2020. Accessed at:
574 https://www.hpsc.ie/a-
575 z/respiratory/coronavirus/novelcoronavirus/casesinireland/COVID-
576 19%20Epidemiology%20report%20for%20NPHET%2001.04.2020%20_website.pdf on
577 05APR2020.
578 HPSC. 2020b. Epidemiology of COVID-19 in Ireland. 15th April 2020. Accessed at:
579 https://www.hpsc.ie/a-
580 z/respiratory/coronavirus/novelcoronavirus/casesinireland/COVID-
581 19%20Epidemiology%20report%20for%20NPHET%2015.04.2020%20_website.pdf on
582 17APR2020.
583 HPSC. 2020c. Epidemiology of COVID-19 in Ireland. 29th April 2020. Accessed at:
584 https://www.hpsc.ie/a-
585 z/respiratory/coronavirus/novelcoronavirus/casesinireland/COVID-
586 19%20Epidemiology%20report%20for%20NPHET%2029.04.2020%20_website.pdf on
587 01MAY2020.
588 HPSC. 2020d. Epidemiology of COVID-19 in Ireland. 6th May 2020. Accessed at:
589 https://www.hpsc.ie/a-
590 z/respiratory/coronavirus/novelcoronavirus/casesinireland/COVID-
591 19%20Epidemiology%20report%20for%20NPHET%2006.05.2020%20v1%20website.pdf
592 on 08MAY2020.
593 Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia Y,
594 Wu W, Xie X, Yin X, Li W, X Y, Gao H, Guo H, Xie J, Wang G, Jiang R, Gao Z, Wang J, Cao B.

595 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan,
596 China. Lancet. 395: 497–506.
597 Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, Ma H, Chen W, Lin Y, Zheng Y, Wang J, Hu Z, Yi Y,
598 Hongbing S. 2020. Clinical characteristics of 24 asymptomatic infections with COVID- 19
599 screened among close contacts in Nanjing, China, Sci China Life Sci 63.
600 Intensive Care National Audit & Research Centre (ICNARC), 2020a. Report on COVID-19 in
601 critical care 08 May 2020. Assessed at:
602 https://www.icnarc.org/DataServices/Attachments/Download/b8c18e7d-e791-ea11-
603 9125-00505601089b on 08MAY2020
604 Intensive Care National Audit & Research Centre (ICNARC), 2020b. Report on COVID-19 in
605 critical care 01 May 2020. Assessed at:
606 https://www.icnarc.org/DataServices/Attachments/Download/f48efee2-d38b-ea11-
607 9125-00505601089b on 02MAY2020
608 Istituto Superiore di Sanità. Sorveglianza Integrata COVID-19 in Italia: AGGIORNAMENTO 22
609 marzo 2020 2020. Accessed at:
610 https://www.epicentro.iss.it/en/coronavirus/bollettino/Infografica_13aprile%20ENG.pd
611 f on 14APR2020
612 Istituto Superiore di Sanità. Sorveglianza Integrata Characteristics of SARS-CoV-2 patients
613 dying in Italy Report based on available data on April 16th, 2020. Accessed 15APR2020.
614 Istituto Superiore di Sanità. Sorveglianza Integrata Characteristics of SARS-CoV-2 patients
615 dying in Italy Report based on available data on April 29th, 2020. Accessed
616 15APR2020https://www.epicentro.iss.it/en/coronavirus/bollettino/Report-COVID-
617 2019_29_april_2020.pdf
618 Ki et al., 2020 Epidemiologic characteristics of early cases with 2019 novel coronavirus
619 (2019-nCoV) disease in Korea Epi & Health 42, Article ID: e2020007, 18 pages
620 https://doi.org/10.4178/epih.e2020007

621 Korean Society of Infectious Diseases, et al., 2020 Report on the Epidemiological Features of
622 Coronavirus Disease 2019 (COVID-19) Outbreak in the Republic of Korea from January
623 19 to March 2, 2020 J Korean Med Sci. 2020 Mar 16;35(10):e112. doi:
624 10.3346/jkms.2020.35.e112
625 Kujawski SA, Wong KK, Collins JP, Epstein L, Killerby ME, Midgley CM, et al. First 12 patients
626 with coronavirus disease 2019 (COVID-19) in the United States. medRxiv.
627 2020:2020.03.09.20032896
628 Lewnard, JA, Liu VX, Jackson ML, Schmidt MA, Jewell BL, Flores JP, Jentz C, Northrup GR,
629 Mahmud A,. Reingold AL, Petersen M, Jewell NP, Young S, Bellows J. 2020. Incidence,
630 clinical outcomes, and transmission dynamics of hospitalized 2019 coronavirus disease
631 among 9,596,321 individuals residing in California and Washington, United States: a
632 prospective cohort study DOI: : https://doi.org/10.1101/2020.04.12.20062943
633 Linton et al., Incubation Period and Other Epidemiological Characteristics of 2019 Novel
634 Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available
635 Case Data. Journ Clin Med. https://doi.org/10.3390/jcm9020538
636 Liu X, Zhou H, Zhou Y, Wu X, Zhao Y, Lu Y, Tan W, Yuan M, Ding X, Zou J, Li R, Liu H, Ewing
637 RM, Hu Y, Nie H, Wang Y. 2020. Risk Factors Associated with Disease Severity and
638 Length of Hospital Stay in COVID-19 Patients. J Infect
639 https://di.org/10.1016/j.jinf.2020.04.008
640 Lo et al., 2020 Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical
641 characteristics of 10 patients with COVID-19 in Macau. Int J Bio Sci 16, 1698 – 1707
642 McMichael T, Currie DW, Clark S, Pogosjans S, Kay M, Schwatz NG, Lewis J, Baer A Lukoff
643 MD, Ferro J, Brostrom-Smith C Rea TD, Sayre MR, Riedo FX, Russell D, Hiatt B,
644 Montgomery P, Rao AK Chow EJ, Tobolowsky F, Hughes MJ, Bardossy AC, Oakley LP,
645 Jacobs JR, Stone ND, Reddy SC, Jerigan JA, Honein MA, Clark TA, Duchin JS. and the CDC

646 Investigation Team. 2020. Epidemiology of Covid-19 in a Long-Term Care Facility in King
647 County, Washington. New Enlg J Med DOI: 10.1056/NEJMoa2005412
648 Myers LC, Parodi SM, Escobar GJ Liu V. 2020 Characteristics of Hospitalized Adults With
649 COVID-19 in an Integrated Health Care System in California JAMA Res Lett
650 doi:10.1001/jama.2020.7202
651 Onder G, Rezza G, Brusaferro A, Case-Fatality Rate and Characteristics of Patients Dying in
652 Relation to COVID-19 in Italy. JAMA. doi:10.1001/jama.2020.4683. Opinion.
653 Paranjpe I, RussakAJ, De Freitas JK, Lala A, Miotto R, Vaid A, Johnson KW, Danieletto M,
654 Golden E, MeyeR D, Singh M, Somani M, Manna M, Nangia U, Kapoor A, O'Hagan R,
655 O'Reilly PF, Huckins LM, Glowe P, Kia A, Timsina P, Freeman RM, Levin MA, Jhang J,
656 Firpo A, Kovatch P, Finkelstein J,Aberg JA, Bagiella E, Horowitz CR, Murphy B, Fayad ZA,
657 Narula J, Nestler EJ, Fuster V, CordonCardo C, Charney DS, Reich DL, Just AC, Bottinger
658 EP, Charney AW, Glicksberg BS, Nadkarni GN, and on behalf of Mount Sinai Covid
659 Infomatics Centre. Clinial charaterisitcs of hospitalized Covid-19 patients in New York
660 City. MedRxiv Preprint. **doi:** https://doi.org/10.1101/2020.04.19.20062117
661 Qian Z, Alaa AM, van der Schaar M, Ercole A 2020 Between-centre differences for COVID-19
662 ICU mortality from early data in England. MedRxiv doi:
663 https://doi.org/10.1101/2020.04.19.20070722.

664 Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. 200 Clinical and epidemiological features of 36
665 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational
666 cohort study Lancet Inf Dis DOI: 10.1016/S1473-3099(20)30198-5.
667 Remuzzi and Remuzzi Covid_19 and Italy: What's next? The Lancet
668 DOI:https://doi.org/10.1016/S0140-6736(20)30627-9.
669 Rhodes A, Ferdinande P, Flaatten H, Guidet B, Metnitz PG, Moreno RP. The variability of
670 critical care bed numbers in Europe. Intensive Care Med. 2012;38(10):1647-53.

https://doi. org/10.1007/s00134-012-2627 8 PMID: 22777516.

Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, and the Northerll COVID-19 Research Group. 2020. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA.* Published online April 22, 2020. doi:10.1001/jama.2020.6775.

Russell, T.W., Hellewell, J., Jarvis, C.I., van Zandvoort, K., Abbott, S., Ratnayake, R., Flasche, S., Eggo, R.M., Edmunds, W.J., Kucharski, A.J. and CMMID COVID-19 working group, 2020. Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020. Eurosurveillance, 25(12).

Spiteri Gianfranco, Fielding James, Diercke Michaela, Campese Christine, Enouf Vincent, Gaymard Alexandre, Bella Antonino, Sognamiglio Paola, Sierra Moros Maria José, Riutort Antonio Nicolau, Demina Yulia V., Mahieu Romain, Broas Markku, Bengnér Malin, Buda Silke, Schilling Julia, Filleul Laurent, Lepoutre Agnès, Saura Christine, Mailles Alexandra, Levy-Bruhl Daniel, Coignard Bruno, Bernard-Stoecklin Sibylle, Behillil Sylvie, van der Werf Sylvie, Valette Martine, Lina Bruno, Riccardo Flavia, Nicastri Emanuele, Casas Inmaculada, Larrauri Amparo, Salom Castell Magdalena, Pozo Francisco, Maksyutov Rinat A., Martin Charlotte, Van Ranst Marc, Bossuyt Nathalie, Siira Lotta, Sane Jussi, Tegmark-Wisell Karin, Palmérus Maria, Broberg Eeva K., Beauté Julien, Jorgensen Pernille, Bundle Nick, Pereyaslov Dmitriy, Adlhoch Cornelia, Pukkila Jukka, Pebody Richard, Olsen Sonja, Ciancio Bruno Christian. First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020. Euro Surveill. 2020; 25 (9): pii=2000178. https://doi.org/10.2807/1560-7917.ES.2020.25.9.2000178

Stier A, Marc G, Berman LM, Bettencourt A. 2020 COVID-19 attack rate increases with city size. MedRxiv preprint. https://doi.org/10.1101/2020.03.22.20041004

697 Stoecklin et al., 2020 First cases of coronavirus disease 2019 (COVID-19) in France:
698 surveillance, investigations and control measures, January 2020. Euro
699 Surv 2020;25(6):pii=2000094
700 Tao Y, Cheng P, Chen W, Wan P, Chen Y, Yuan G, Chen J, Huo D, Guan G, Sun D, Tan J, Yang
701 G, Zeng W, Zhu C. 2020 High incidence of asymptomatic SARS-CoV-2 infection,
702 Chongqing, China BMJ Yale Available on MedRxiv
703 https://doi.org/10.1101/2020.03.16.20037259.
704 Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z, Chen H, Wang D, Liu N, Liu D, Chen G, Zhang Y, Li
705 D, Li J, Lian H, Niu S, Zhang L, Zhang J. 2020 Characteristics of COVID-19 infection in
706 Beijing J Inf 80, 401-406 https://doi.org/10.1016/j.jinf.2020.02.018
707 Tricco AC, Erin Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ,
708 Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L,
709 Aldcroft A, Wilson MG, Garritty G, Lewin S, Godfrey CM, Macdonald MT, Langlois EV,
710 Soares-Weiser K, Moriarty J, Clifford T, Tunçalp Ö, Straus SE, 2020. PRISMA extension
711 for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 169: 467 –
712 473.
713 Valente-Acosta B, Hoyo-Ulloa I, Espinosa-Aguilar L, Mendoza-Aguilar R, Garcia-Guerrero J,
714 Ontañon-Zurita D, Gomez-Gomez B, Fueyo-Rodríguez O, Vera-Zertuche JM, Anzola-Arias
715 RJ, Jiménez-Ceja JV, Horta-Carpinteyro D, OlveraGuzman C3,5, Aguirre-Sanchez J5,
716 Franco-Granillo J, Jauregui-Camargo L, SadaDíaz E, Saavedra-Perez-Salas R, Palomar-
717 Lever A, Moreno-Sánchez F 2020 COVID-19 severe pneumonia in Mexico City – First
718 experience in a Mexican hospital MedRxiv Preprint.
719 **doi:** https://doi.org/10.1101/2020.04.26.20080796
720 Verity et al.,2020 Estimates of the severity of coronavirus disease 2019: a model-based
721 analysis Lancet Inf Dz 2020. Published Online March 30, 2020.
722 https://doi.org/10.1016/S1473-3099(20)30243-7

723 Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019
724 novel coronavirus infected pneumonia in Wuhan, China. JAMA. 2020.
725 https://doi.org/10.1001/jama.2020. 1585.
726 Wen et al., 2020 Epidemiological and clinical characteristics of COVID-19 in Shenzhen, the
727 largest migrant city of China https://doi.org/10.1101/2020.03.22.20035246
728 World Health Organization (WHO). 2020. Report of the WHO-China Joint Mission on
729 Coronavirus Disease 2019 (COVID-19) 2020 [cited 2020 1 March]. Available from:
730 https://www.who.int/docs/defaultsource/coronaviruse/who-china-joint-mission-on-
731 covid-19-final-report.pdf.
732 World Health Organization (WHO). Rapid reviews to strengthen health policy and systems: A
733 practical guide. 2017. Eds Andrea C. Tricco, Etienne V Langlois and Sharon E Straus.
734 Published by the World Health Organization (WHO).
735 Wu JT, Leung K, Bushman, M, Kishore N, Niehus R, de Salazar PM, Cowling BJ, Lipsitch M,
736 Leung GM. 2020. Estimating clinical severity of COVID-19 from the transmission
737 dynamics in Wuhan, China. Nature Medicine 26; 506 – 510.
738 Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus
739 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From
740 the Chinese Center for Disease Control and Prevention. *JAMA.* Published online
741 February 24, 2020. doi:10.1001/jama.2020.2648 5.
742 Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019
743 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series.
744 BMJ. 2020;368: m606.
745 Yang X, Yu Y, Xu J et al (2020) Clinical course and outcomes of critically ill patients with SARS-
746 CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational
747 study. Lancet Respir Med. https://doi. org/10.1016/S2213-2600(20)30079-5

Yuan et al, The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. Infammation Research. https://doi.org/10.1007/s00011-020-01342-0.

Young, EB et al., 2020. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. Original Investigation *JAMA.* Original Investigation March 3, 2020Published online March 3, 2020. doi:10.1001/jama.2020.3204.

Zhang C, Gu J, Chen Q, Deng N, Li J, Huang L, Zhou X. 2020a Clinical Characteristics of 34 Children with Coronavirus Disease-2019 in the West of China: a Multiple-center Case Series https://doi.org/10.1101/2020.03.12.20034686 doi: medRxiv preprint.

Zhang G, Hu C, Luo L, Fang F, Chen Y, Li J, Peng Z, Pan H. 2020b. Clinical features and outcomes of 221 patients with COVID-19 in Wuhan, China MedRxiv Preprint. D**oi:** https://doi.org/10.1101/2020.03.02.20030452.

Zhao J, Yang Y, Huang H, Li D, Gui D, Lu X, Zhang Z, Liu L, Liu T, Liu Y, He Y, Sun B, Wei M, ang G, Wang X, Zhang L, Zhou X, Xing M, Wang PG. 2020 Relationship between the ABO Blood Group and the COVID-19 Susceptibility. MedRxiv preprint. doi: https://doi.org/10.1101/2020.03.11.20031096.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020.

768 **Figure legends**

769

770 Figure 1. The crude mortality rate (CMR) expressed as the percentage of notified deaths to
771 cases over time, from number of days lapsed since the notification of the tenth case for
772 12 selected European countries. Data tabulating the notified cases and deaths from all
773 countries is available from the European Centre for Disease Control and Prevention;
774 https://www.ecdc.europa.eu/en/publications-data/download-todays-data-geographic-
775 distribution-covid-19-cases-worldwide

776

777 Figure 2. The cumulative number of notified cases (grey bars) in Ireland between 30th March
778 and 23rd April; the percentage of COVID positive cases that were hospitalised (black
779 line); and those that were admitted to ICU (maroon line) for the same period. Data
780 extracted from publicly available data published by the Health Protection Surveillance
781 Centre (HPSC), Ireland.

782

783 Figure 3. The median (maroon square) and 25th (blue diamond) and 75th percentile (green
784 diamond) for eight relevant articles and reports describing the median (and IQR)
785 length of stay in hospital due to COVID-19 infection. Two studies (Linton et al., 2020;
786 Yuan et al., 2020) reported means (maroon circle) and confidence intervals
787 (diamonds); while one study (Liu et al., 2020) reported median (square) and range (X)
788 for length of stay following COVID-19 infection. The Italian report (COVID-19 Group,
789 2020) indicates a median of 5 days; no estimate of variance was reported. A subgroup
790 of the Valente-Acosta (2020) article is greyed, as only 4 remained in the group.

791

792 Figure 4. The median (blue diamond) and 25th (maroon square) and 75th percentile (green
793 diamond) for eight relevant articles and reports describing the median (and IQR)

length of stay in an ICU due to COVID-19 infection. The Italian report (COVID-19 Group, 2020) indicates a median of 8 days (including ICU stay for deceased patients); no estimate of variance was reported. The UK report separates survivors from those who have died in care, the authors also indicate bias towards shorter lengths of stay as this cohort has completed their ICU stay.

801 Figure 1.

802



803

804

805

806

807

808

809

810

811

812

813

Figure 2.


Cumulative cases
5000
10000
15000
20000
25000
Percentage of cases (%)
0
5
10
15
20
25
30
35
40
45
50
01apr2020
08apr2020
15apr2020
22apr2020
29apr2020
06may2020
Date

Figure 3


China; Cao et al., 2020; n = 199; 22 % died
China; Guan et al., 2020. n = 1099 non severe
China; Guan et al., 2020; severe
China; Linton et al., 2020; n= 34; died
China; Liu et al., 2020; n = 39; severe pneumonia
China; Liu et al., 2020; n = 61; pneumonia
China; Wang et al., 2020; n = 450; mild
China; Wang et al., 2020; n = 47; all
China; Wang et al., 2020; n = 538; all
China; Wang et al., 2020; n = 88; severe
China; Yuan et al., 2020; N = 94; All
China; Yuan et al., 2020; N = 94; moderate
China; Yuan et al., 2020; N = 94; severe
China; Zeng et al., 2020; 137; mild hospitatised
China; Zhou et al.,2020; n=191; all
China; Zhou et al.,2020; non surv
China; Zhou et al.,2020; surv
Italy; COVID-19 Group, 2020; n = 19,996; all died
Korea; Ki et al., 2020; n = 28;
Macau; Lo et al., 2020; 5
USA; Argenziano et al., 2020; n = 1000; 21 % died
USA; Argenziano et al., 2020; n = 614; 14 % died (non icu)
USA; Badawi et al., 2020; n = 465; All
USA; Paranjpe et al., 2020; n= 2,199; all; 29 % died
USA; Petrilli et al., 2020; n= 1,999
USA; Richardson et al., 2020; died
USA; Richardson et al., 2020; discharged
USA; Richardson et al., 2020; n = 2634
0
5
10
15
20
25
30
35
40
45

Figure 4.


China; Cao et al., 2020; n = 155; Survivor
China; Cao et al., 2020; n = 199; RCT
China; Cao et al., 2020; n = 44; Died
China; Fan et al., 2020; n = 101; Died (all died)
China; Yang et al., 2020; n = 52; Died (all died)
China; Zhou et al.,2020; n = 132; Suriviors
China; Zhou et al.,2020; n = 191; All
China; Zhou et al.,2020; n = 54; Died
Italy; COVID-19 Surveillance Group, 2020; included ICU; Died
Italy; Graselli et al. 2020b; n = 1581; All
Italy; Graselli et al. 2020b; n = 256 Survivors
Italy; Graselli et al. 2020b; n = 405 Died
Italy; Graselli et al. 2020b; n = 920; Contituing care
Mexico; Valente Acosta et al., 2020; n = 20; Severe (to discharge)
Mexico; Valente Acosta et al., 2020; n = 4; Critical (to discharge)
Switzerland; Ceruti et al., 2020; n = 41; ICU only; All (discharged)
UK; ICNARC report; n = 3,271 Suriviors
UK; ICNARC report; n =2,872; Died
USA; Argenziano et al., 2020 n = 236; includes continuing care
USA; Badawi et al., 2020; 84.2 %; Mechanically ventilated
USA; Badawi et al., 2020; n = 465; All
USA; Bhatraju et la., 2020; n = 12; Survived or continuing care
USA; Bhatraju et la., 2020; n = 24; 50 % died
USA; Cummings et al., 2020; n= 86; Died
USA; Petrilli et al., 2020; n = 225; Resolved (died or discharged)
USA; Petrilli et al., 2020; n = 309; Continuing care
0
5
10
15
20
25
30
35

Table 1. A summary of published articles and reports relating to hospitalisation following COVID-19 infection, by country.

Paper	Location	Timing	Demographics	Proportion higher level care	Time from (days, IQR)	Outcomes	Comments
China							
Huang et al., 2020 PR	Wuhan, China	16DEC2019 to 02JAN2020	41 patients median Age 49 (IQR 41-58) Underlying dx 13 (32 %) Contact to Hunan mkt 27 (66 %)	13 of 41 to ICU 4 of 41 mech vent 2 of 41 ECMO	Time from symptoms: To Hospital 7 ,4 – 8 To dysnoea 8, 5 - 13 To ARDS 9, 8 – 14 Mech vent 10.5, 7 - 14 ICU 10.5, 8 - 17	6 (15%) patients died 28 (68 %) discharged	
Chen et al., 2020	Wuhan, China	01JAN2020 to 20JAN2020	99 lab confirmed patients, 49 (49 %) exposure to Hunan market. Mean age 55.5 (SD 13.1), 67 male, 32 female. 50 (51 %) chronic conditions.	31 (31 %) dypsnoa 17 (17 %) ARDS 75 (76 %) Oxygen thx Mechanical ventilation Non invasive 13 (13%); median 9, IQR 7 to 19, range 40 to 22 days Invasive 4 (4 %) 17, IQR 12 - 19, range 3 to 20 days CRRT 9 (9 %) ECMO 3 (3 %)		11 (11%) died 31 (31 %) discharged 57 (58 %) still hospitalized by study cut off	
Guan et al., 2020 PR	China – 30 provinces	To 31JAN2020	1099 patients. Median age 47 (range 35-58) 41.9 % female	453 (41.3 %) oxygen 67 (6.1 %) mech vent 55 (5 %) to ICU		15 (1.4 %) died 93 % continued hospitalisation	
Zhou et al.,2020 PR	Wuhan, China	To 31JAN2020	191 patients. Median age 56 (IQR 46 – 67, Range 18-87 Non surv (median 69 yrs) Surv (median 52 yrs) Pre-exisitng 48 %		Time to development: dysnoea 7, 4 to 9, to ARDS 12, 8 to 15 to ICU 12, 8 to 15	54 (28 %) of 191 died 137 (72 %) discharged	Median duration of shedding 20 days (longest 37 days)
Linton et al., 2020 PR	China	To 31JAN2020	Onset hospital to admission: Living n = 155 Dead n= 34 Hospital admission to death n= 29 Male 58 %, age rage 30 – 59 (9 missing)	NR	Onset to hospital admission 3.3, CI 2.9 – 5.3 (living) 6.5, CI 5.0 – 7.8 (dead)		Article that collated data from open source and news reports
Wang et al., 2020 JAMA. PR	Wuhan, China	01JAN2020 to 03FEB2020	138 patients, median age 56, IQR 42 - 68, range 22-92 yrs. 75 (54.3 % male. ICU patients n = 36 older median age 66 vs 51, underying conditions 26 (72 %) vs 38 (37.3%).	ICU 36 of 138 (26.6 %) ARDS 22 of 36 (61.1 %) High flow O2: 4 (11 %) Non invasive ventilation 15 (41.7 %) 17 (47.2 %) invasive ventilation 4 of 36 ECMO	Time to dyspnoea 5 days To admission 7 days, ARDS 8 days	6 patients (4.3 %) died 47 (34.1%) discharged remainder hospitalised at study cut off.	Hospital assoc. transmission suspected 40 (29 %) HCW and 17 (12.3 %) hospitalized patients.
Yang et al., 2020	Wuhan, China	DEC 2019 to 26JAN2020	Some 52 (of 710 in cohort) critically ill adult patients confirmed cases admitted to ICU. Mean age 59·7 (SD 13·3) years, 35 (67 %) male, 21 (40 %) had pre-existing conditions	35 (67 %) ARDS 37 (71 %) mechanical ventilation Compared to survivors, non-survivors were older (64·6 years vs. 51·9 years) more likely to develop ARDS; 26 (81 %) vs. 9 (45 %) patients; and more likely to receive mechanical ventilation; 30 (94 %) vs. 7 (35 %) patients	Interval onset to ICU admission: Surv: 9, 6 – 12. Non-surv 11,7 – 14.	32 % died by 28 days	Hospital-acquired infection occurred in seven (13·5 %) patients. APACHE II and SOFA score lower in survivors vs. non survivors.
Fan et al., 2020 Pre-print	Wuhan China	30DEC2019 to 16FEB2020	101 patients, mean age 65.5 years (range 24 to 83). 64 males, 37 females. All died. Majority underlying, 25.7 % two conditions.	All (101, 100 %) oxygen therapy, 84 (83.17 %) non-invasive ventilator or high flow oxygen, 79 (78.2%) invasive ventilation. 7 patients ECMO, 8 treated with CRRT	Onset to hospital 11, 8 to 13.5 To death 21, 17 to 27.5 To ARDS 12, 9 to 14 ARDS to invasive mechanical ventilation 3, 0 to 6. Duration invasive mechanical ventilation 5, 2 to 8; range 1 to 31 days).	All died – criteria for inclusion was death	Early paper - 57 patients lab confirmed, 44 clinically consistent
Xu et al., 2020	Zhejiang province China	10JAN2020 to 26JAN2020	62 patients median age 41 yrs (IQR32 – 52 yrs). 35 (56 %) male. 20 of 62 (32 %) had underlying condition.	ICU 1 of 62 ARDS 1 of 62 Mechanical ventilation 1 of 62	Two patients (3%) shortness of breath on admission. Median time from exposure to onset of	61 of 62 (98 %) hospitalised 0 of 62 (0 %) died	Less severe presentations observed in Zhejiang Province compared with

					was 4, 3-5), Onset to admission was 2, 1-4.		Wuhan
Wen et al., 2020 Pre-print	Shenzhen,China	01JAN2020 to 28FEB2020	417 confirmed cases 37 (8.9 %) mild 344 (82.5 %) moderate. 36 (8.6 %) severe or critical. Mean age 45.4 years. 220 (52.8 %) female.		Time to: Onset to medical visit 1, 0 – 3. Medical visit to admission 0, 0 to 2. admission to PCR result 1, 1 – 3	3 (0.7 %) died 299 (71.7%) discharged. 115 (27.6 %) hospitalized at study cutoff	Notes longer time from first medial visit to admission greater severity. Surv cases more likely to severe illness – warning to treat earlier .
Wu and McGoogan 2020 Opinion	China	To 11FEB2020	72,314 Cases (as of February 11, 2020) Confirmed cases: 44,672 (62%) Suspected cases: 16,186 (22%) Diagnosed cases: 10,567 (15%) Asymptomatic cases: 889 (1%)	Spectrum of disease (N = 44,415) Mild: 81 % (36,160 cases) Severe: 14 % (6,168 cases) Critical: 5 % (2,087 cases)		1023 of 44,672 (2.3 %) died 208 of 1,408 (14.8%) aged 80+ years 312 of 3,918 (8.0 %) aged 70-79 years 1,023 of 2,087 (49.0 %) critical cases died	HCW infected 1,716 of 44,672 (3.8 %) overall 1,080 of 1,716 (63 %) in Wuhan 247 of 1,668 (14..8%) classified severe or critical 5 died
Singapore							
Young et al., 2020 Case Series	Singaore	To 25FEB2020	18 patients. Median age was 47 yrs, 50 % male, 50 % female	6 of 18 (33.3 %) Oxygen2 of 18 (11.1 %) to ICU 1 of 18 (5.6 %) mech vent			
Korea							
Ki et al., 2020 Epi Health Special Article	Korea	20JAN2020 to 10FEB2020	28 patients; 15 (53.6 % male. Med age 42 yrs, range 21-73.		Onset to diagnosis 4, range 0 – 16. Onset to quarantine / isolation 3, range 0 to 15 days.		3 asymptomatic 4 discharged other continue hospitalisation – none listed as serious at study cut off.
Macau							
Lo et al., 2020 Int J Biol Sci PR	Macau	21JAN2020 to 16FEB2020	10 cases. Median age 54 years (IQR 27 to 64). Two patients were assigned a mild classification, four moderate and four severe. 5 of 10 pre-existing condition.	10 of 10 hospitalised, 0 of 10 to ICU. 0 of 10 ARDS		5 discharged and 5 remained hospitalized at study cutoff.	
Italy							
Graselli et al. 2020 Opinion	Lombardy Italy	20FEB2020 to 07MAR2020	3,420 cases	359 of 3420 (16 %) ICU			
Cereda et al.,2020 Pre-print	Lombardy Italy	20FEB2020 to 08MAR2020	5,830 cases. 204 asymptomatic Median age 69 yrs (ranged 1 month to 101 yrs). 62% male	204 asymptomatic 5,626 reported symptoms 47 % hospitalized 18 % ICU		346 died highest in older groups 14 % in 75 + yrs	
Graselli et al. 2020b PR	Lombardy Italy	20FEB2020 to 18MAR2020	1,591 patients admitted to ICU	1287 of 1300 (99 %) required respiratory support; 1150 (88 %), mechanical ventilation 137 (11 %,) received non-invasive ventilation.		ICU mortality 26 %. Older patients (n = 786; age 64 years and older) had higher mortality (36 %) than younger patients (n = 795; age aged 63 years or less (15 %)	ICU patients only; incluson criterion
COVID-19 Surveillance Group, 2020 Health report	Italy	Up to 29APR2020	25,452 deceased patients. Median age was 81 years (IQR 73 to 87). Females 9,684 (38 %). Overall, 3.8 % presented with a no pre-existing condition, 14.5 % with 1, 21.4 % with 2, and 60.3 % with 3 or more. Number of patients transferred to ICU not reported.	ARDS occurred in 96.7 % of cases	Median onset symptoms to death 10 days, onset to hospitalization was 5 days (IQR or ranges not presented)	All patients died (n = 25,452). ARDS in 97.1 % of cases,acutre renal failure in 23,3 %. Superinfection 12.6 % and acute caridac injury in 10.9 % of cases.	All patients died; inclusion criterion It is not clear what number of patients were transferred to ICU care.
Spain							
Borobia et	Madrid,	25FEB2020	2,226 of 3,127 patients	2,226 of 3,127 patients	Median onset symptoms	460 of 2,226 died	Most frequent

al., 2020	Spain	to 19APR2020	were hospitalized. Median age 61, 46 – 78, 52 % female. 78 % at least one pre-existing condition. 41 % hypotensive, 19 % Chronic heart disease, 17 % DM.	were hospitalized. 460 of 2,226 died (20.7 %); or 1,766 of 2,226 (79.3 %) discharged. 237 (10.6 %) admitted to ICU, 116 continued care ICU, 55 died, 20 discharged, 46 discharged to acute bed	to hospital admission 6, 3 – 9 d	(20.7 %); 1,766 of 2,226 (79.3 %) discharged	complication acute confusional syndrome 197 (9 %), acute kidney failure 173 (8 %) and ARDS 109 (5 %).
Switzerland							
Ceruti et al., 2020	Switzer-land	14MAR2020 to 12APR2020	41 ICU patients. mean age 64 (/- 16.5) years, 35 (85 %) male.	41 of 310 (13.2 %) admitted to clinic admitted to ICU. 54 with DNR not considered for ICU admittance.		10 died (24 %); 2 transferred out; 24 (61 %) discharge	41 patients addmitted to ICU from 310 at clinic. 34 (83 %) required mechanical ventilaton. 25 (61 %) to discharge.
USA							
Kujawski et al., 2020 Case series	USA 6 States 6 of 12 CA	20JAN2020 to 05FEB2020	12 patients. Median age 53 yrs (range 21 to 68). 8 male. 4 of 5 with underlying conditions hospitalised	Hospitalisation 7 of 12. 5 of 12 Dyspnoea 4 of 12 supplemental oxygen ICU 1 of 12 patient	Onset to resolution 14 range 6 to 20	11 of 12 discharged or home isolation 1 hospitalized at study cut off (in ICU)	Case series n = 12.
CDC COVID-19 Response Team Report	USA	12FEB2020 to 16MAR2020	4,226 cases. Hospitalization status missing 1,514 cases. ICU status missing or 2,253 cases. Illness outcome or death missing or unknown for 2,001 cases	Hospitalisation in 20.7 to 31.4 % of cases, with ICU admission required for 4.9 to 11.5 %.		Case fatality estimates: ≥85 years, ranging from 10% to 27%, 65 – 84 yrs: 3% to 11% persons, 55 – 64 years: 1% to 3%	Estimate range presented to account for missing data
Badawi et al., 2020	USA New York City	23MAR2020 to 06APR2020	Hourly results from 186 ICU beds from 14 ICUs and 9 hospitals. 465 patients.	Mean age 63.7 (SD +/- 14.3). 312 (67 %) male.		During pandemic - DRS highest reached 37.5 (1.5 – 71.5) versus (0.9 (0.2 to 7.1; pre pandemic. Last DRS before ICU discharge: 17.5 (0.8 – 71) vs 0.3 (0.1 – 1.2 pre-pandemic.	
Myers et al., 2020	USA, Californi a	01MAR2020 to 30MAR2020	377 of 1,299 est positive hospitalised. Median age 61, 50 – 73 years. 212 (56 %) male.	Hospitalisaton 29 % (377 of 1,299 test positives. 113 (8.7 %) to ICU		Of 321 with resolved status; 50 (15.6 % died). 34 of 68 (50 %) ICU patients died.	Invasive ventilation in 110 of 377 (29 %) patients, 103 of 113 (91 %) ICU patients.
Cummings et al., 2020	US, New Yord	02MAR2020 to 01APR2020	257 of 1,150 hospitalised patients categorised critical. Meidan age 62, 51 – 72. 170 of 257 ((66 %) male. 82 % at least one pre-existing condition.	Of those enrolled 257 of 1,150 (22 %) transferred to ICU,	Onset to presentation 6 (SD +/- 5) d.	86 of 257 (33 %) died in hospital. 122 of 257 continuing care. 4 transferred. 45 of 257 discharged alive.	201 of 257 received invasive mechanical ventilation. 13, 9 – 17 d.
Paranjpe et al, 2020	USA New York City	27FEB2020 to 02APR2020	2,199 COVID-19 positive hospitalised patients. Median age 65, 75 if died, 59 if discharged. Pre-existing conditions in 46 % of discharged, 64 % of died patients.	All hospitalised. 1,078 completed stay, 36 % admitted to ICU care during stay.		Of 1,078 with resolved status; 768 (71 %) dischaged, 310 (29 %) died.	All hospitalised. 1,078 completed stay
Richardson et al., 2020	USA, New York	01MAR2020 to 04APR2020	5700 patients. Median age 63, 52 – 75 yrs. 2263 (39.7 %) female. 350 (6.1 %) no pre-existing condition, 359 (6.3 %) had 1 pre-existing condition, 4,991 (88 %) > 1 pre-existing condition.	All admitted to 1 of 12 hospitals in New York. 373 of 2634 (14.2 %) of patients who completed stay trasnferred to IC. 320 (12.2 %) required mechanical ventilation.			553 of 2,634 (21 %) died. Mortality for mechanically ventilated patients 88.1 %. 45 (2.2 %) patients were re-admitted.
Argenzian o et al., 2020	USA, New York	01MAR2020 to 05APR2020	1000 patients. 150 ED only treatment, 614 admitted to general wards, 236 admitted to ICU. Median age 63, 50 75. 596 (60 %) male. Only 82 (8.2 %) no pre-existing	Of 2,423 tested, 1,403 positive, 1,132 received ED or hospital care. 1000 followed up. 23.6 % admitted to ICU care.	Time to initial intubation (136 patients) was bimodal, 3 4 d, or 9 days post onset.	At cutoff 90 (9 %) continuing care 699 (70 %) discharged; 211 (21.1 %) died. 103 of 236 (43.6 %)	Of the 150 ED only patients; 85 % discharged, 14.7 % died before admission. 233 (23.3 %)

			conditions. 75 % BMI > 25.			ICU cases died.	intubated at least once. Duration of mechanical ventilation 6, 2 – 13 days if died; 9, 6.5 – 12 d if discharged.; and 28, 22.5 – 32 d if continuing care.
Lewnard et al., 2020	USA California and Washington state	To 09APR2020	1,277 patients. Median age 60, 47 – 72. 56.8 % male. 817 of 1,299 (64 %) completed stay.	158 of 617 (25.6 %) admitted to ICU (data not available from Washington State) Estimates of admissons to ICU 41.9 % (34.1 – 51.4 %)		Mortality 119 of 772 (15.4 %). Esimtates for ICU fatalities 17.8 % (14.3 – 22.2 %)	Adjusted for censored data and status of new hospitalizations - hence estimates calculated.
Ireland							
HPSC Ep Team 2020a	Ireland	To 30MAR2020	2,990 confirmed cases. Median age 48, range 0 to 99 years.	Hospitalisaton in 834 of 2,990 (27.9 %) of cases. ICU in 126 of 2,990 cases (4.2 %)			84 (2.8 % died)
HPSC Ep Team 2020b	Ireland	To 13APR2020	11,261 confirmed cases. Median age 48, range 0 to 106 years.	Hospitalisaton in 1,968 of 11,261 (17.5 %) of cases. ICU in 280 of 11,261 cases (2.5 %)			435 (3.9 %) died *Data inlcudes HPSC Ep Team 2020b*
HPSC Ep Team 2020c	Ireland	To 27APR2020	19,723 confirmed cases. Median age 49 range 0 to 106 years.	Hospitalisaton in 2,669 of 19,723 (13.5%) of cases. ICU in 355 of 19,723 cases (1.7 %)			962 (4.9 %) died *Data inlcudes HPSC Ep Team 2020a 2020b and 2020c and 2020d above*
HPSC Ep Team 2020d	Ireland	To 04MAY2020	21,908 confirmed cases. Median age 49 range 0 to 106 years.	Hospitalisaton in 2,878 of 21,908 (13.1%) of cases. ICU in 373 of 21,908 cases (1.7 %)			1,128 (5.1 %) died *Data inlcudes HPSC Ep Team 2020a 2020b and 2020c and 2020d and 2020e above*

848

849 Table 2. A summary of published articles and reports relating to length of stay in an non ICU settings following COVID-19 infection, by country.

Paper	Location	Timing	Demographics	LOS, median (days), IQR	Outcomes	Comments
China						
Guan et al., 2020 PR	China 30 provinces	To 31JAN2020	1099 patients. Median age 47 (range 35-58) 41.9 % female	11, 10 – 13 non severe 13, 11.5 to 17 severe	15 (1.4 %) died 93 % continued hospitalisation	
Zhou et al.,2020 PR	Wuhan, China	To 31JAN2020	191 patients. Median age 56 (IQR 46 – 67) Non surv (median 69 yrs) Surv (median 52 yrs) Pre-exisitng 48 %	11, 7 – 14 All 7.5, 5 – 11 Non surv 12, 9 – 15 Surv	54 (28 %) of 191 died 132 (72 %) discharged	Median duration of shedding 20 days (longest 37 days)
Linton et al., 2020 PR	China	To 31JAN2020	Onset to hospital admission: Living n = 155 Dead n= 34 Hospital admission to death n= 29 Male 58 %, age rage 30 – 59 (9 missing)	8.8, CI 7.2 – 10.8 died only, n = 34		Article that collated data from open source and news reports
Wang et al., 2020 JAMA. PR	Wuhan, China	01JAN2020 to 03FEB2020	138 patients, median age 56, IQR 42 - 68, range 22- 92 yrs. 75 (54.3 % male. Hospital assoc. transmission suspected 40 (29 %) HCW and 17 (12.3 %) hospitalized patients. ICU patients n = 36 older median age 66 vs 51, underlying conditions 26 (72 %) vs 38 (37.3%).	10, 7 to 14 discharged n = 47	6 patients (4.3 %) died 47 (34.1%) discharged remainder hospitalised at study cut off.	
Cao et al., 2020	Wuhan China	18JAN2020 to 03FEB2020	199 patients; age 58, 49 – 68. 120 (60 %) male.	15, 12 - 17	44 (22.1 %) died	open-label, individually randomized, controlled trial
Fan et al., 2020 Pre-print	Wuhan China	30DEC2019 to 16FEB2020	101 patients, mean age 65.5 years (range 24 to 83). 64 males, 37 females. All died. Majority underlying, 25.7 % two conditions.	Days in general ward 0 (0 to 4 days). 54 of 101 transferred to ICU	All died – criteria for inclusion was death	Early paper - 57 patients lab confirmed, 44 clinically consistent
Yuan et al., 2020 PR	Zhenzhen China	11JAN2020 to 13FEB2020	94 discharged patients with COVID-19 infection Median age 40 (range 1 to 78 years). Males acocunted for 42 of 94 cases.	mean 14.3 (CI 13.6 - 15.0) All 12.9 (CI 11.4 - 14.4) moderate n = 8 16.4 (CI 14.8 - 17.9) Severe cases n = 11		All 94 patients discharged. Inclusion criterion.
Wang et al., 2020-04-21 rePrint	Sichuan China	16JAN2020 to 04MAR2020	538 lab confirmed COVID. Median age 45 (271 (50%) were over 45). 285 (53 %) were male. 450 (84 %) classified mild illness.	19, 14 – 23 (all) 21, 14 – 24 Over 45 yrs 18, 13 – 22 Under 45 yrs 19, 14 – 24 Male 19, 14 – 23 Female 19, 14 – 23 Mild cases 23, 15 – 26 Severe cases		364 of 538 discharged 174 unresolved or died
Zeng et al., 2020	Beijing and Wuhan, China	05FEB2020 to 20MAR2020	137 mild patients. Median age 52 (40 – 64) years. 74 (54 %) male.	25, 14 – 33 Mild LOS severe cases not reported		
Korea						
Ki et al., 2020 Epi Health Special Article	Korea	20JAN2020 to 10FEB2020	28 patients; 15 (53.6 % male. Med age 42 yrs, range 21-73.	Dx to discharge: 12.5, range 7 to 17.		3 asymptomatic 4 discharged other continue hospitalisation – none listed as serious at study cut off.
Macau						
Lo et al., 2020 Int J Biol Sci PR	Macau	21JAN2020 to 16FEB2020	10 cases. Median age 54 years (IQR 27 to 64). Two patients were assigned a mild classification, four moderate and four severe. 5 of 10 pre-existing condition.	20, 19 – 21		5 remained hospitalised at study cutoff
Italy						
COVID-19 Surveillance Group, 2020 Health report	Italy	Up to 29APR2020	25,452 deceased patients. Median age was 81 years (IQR 73 to 87). Females 9,684 (38 %). Overall, 3.8 % presented with a no pre-existing condition, 14.5 % with 1, 21.4 % with 2, and 60.3 % with 3 or more.	5 , variation not presented	All patients died (n = 25,452). ARDS in 97.1 % of cases, acute renal failure in 23,3 %. Superinfection 12.6 % and acute caridac injury	All patients died; inclusion criterion It is not clear what number of patients were transferred to ICU care.

			Number of patients transferred to ICU not reported.		in 10.9 % of cases.	
USA						
Paranjpe et al, 2020	USA New York City	27FEB2020 to 02APR2020	2,199 COVID-19 positive hospitalised patients. Median age 65, 75 if died, 59 if discharged. Pre-existing conditions in 46 % of discharged, 64 % of died patients.	7.7, variation not presented	Of 1,078 with resolved status; 768 (71 %) dischaged, 310 (29 %) died.	All patients hospitalised, 36 % admitted to ICU, no LOS specific to ICU presented. Suggests LOS acocuntsfor censored data (50% completed stay).
Petrilli et al., 2020	New York USA	01MAR2020 to 02APR2020	4,103 positive cases, of which 1,999 hospitalised. mean 52 yers (36 – 65). 2072 (50.5 %) male. 1,999 hospitalised, 650 critical, 116 died or hospsice, 534 to ICU.	4.8, 3.3 – 7.6 (if resolved)	292 of 1,999 (14.6 %) died or transferred to hospice. 981 followed to discharge	1,999 of 4,103 positive were hospitalised.
Richardson et al., 2020	USA, New York	01MR2020 to 04APR2020	5,700 patients. Sequentially hosptialised. Median age 63, 52 – 75 yrs. 2263 (39.7 %) female.	4.1, 2.3 – 6.8 3.9, 2.4 – 6.7 discharged 4.8, 2.3 – 7.4 died	553 of 2,634 (21 %) died	2,634 of 5,700 admitted followed to death or discharge
Argenziano et al., 2020	USA, New York	01MAR2020 to 05APR2020	1000 patients. 150 ED only treatment, 614 admitted to general wards, 236 to ICU. Median age (all) 63, 50 75. 596 (60 %) male. Only 82 (8.2 %) no pre-existing conditions. 75 % BMI > 25. Median age (n = 614 hospitalised non icu) 64, 51 – 77. 353 of 614 (57.5 %) male. 57 of 614 (9.3 %) no pre-existing conditions. 75 % BMI > 25	6, 3 – 14 All n=1,000 4, 2 – 8 Hospitalised non icu	At cutoff 90 (9 %) continuing care 699 (70 %) discharged; 211 (21.1 %) died. 86 of 614 (14 %) hospitalised cases died.	Of the 150 ED only patients; 85 % discharged, 14.7 % died before admission.
Badawi et al., 2020	USA New York City	23MAR2020 to 06APR2020	Mean age 63.7 (SD +/- 14.3). 312 (67 %) male.	6, 3 – 10 (including ICU)		Study examined ICU occupancy. During pandemic - DRS highest reached 37.5 (1.5 – 71.5) versus (0.9 (0.2 to 7.1; pre pandemic. Last DRS before ICU discharge: 17.5 (0.8 – 71) vs 0.3 (0.1 – 1.2 pre-pandemic.
Lewnard et al., 2020	USA California and Washington state	To 09APR2020	1,277 patients. Median age 60, 47 – 72. 56.8 % male. 817 of 1,299 (64 %) completed stay.	Mean reported 11.3, IQR 5.1 – 15.6, normal range (NR) 0.9 – 31.3 All 10.7 (surv) NR 0.8 – 30.1 13.7 (non surv) NR 1.7 – 34.6	Mortality at cutoff 09APR 119 of 772 (15.4 %).	Adjusted for censored data

850

851

852

853

854

855

856

857

858

859

860
861 Table 3. A summary of published articles and reports relating to length of stay in an ICU setting following COVID-19 infection, by country.

Paper	Location	Timing	Demographics	ICU; LOS median (days), IQR	Outcomes	Comments
China						
Chen et al., 2020	Wuhan, China	01JAN2020 to 20JAN2020	99 patients. Mean age 55.5 (SD 13.1), 67 male, 32 female. 50 (51 %) chronic conditions.	9 and 11 days ICU n= 2 both died	11 (11%) died 31 (31 %) discharged 57 (58 %) still hospitalized by study cut off	Lab confirmed
Zhou et al.,2020 PR	Wuhan, China	To 31JAN2020	191 patients. Median age 56 (IQR 46 – 67) Non surv (median 69 yrs) Surv (median 52 yrs) Pre-exisitng 48 %	8, 4 – 12 ICU 7, 2 -9 Surv 8, 4 -12 Non surv	54 (28 %) of 191 died 132 (72 %) discharged	
Yang et al., 2020	Wuhan, China	DEC 2019 to 26JAN2020	52 critically ill patients of 710 in cohort admitted to ICU. Mean age 59·7 (SD 13·3) years, 35 (67 %) male, 21 (40 %) had pre-existing conditions	7, 3–11 ICU to death		ICU care only included
Cao et al., 2020	Wuhan China	18JAN2020 to 03FEB2020	199 patients; age 58, 49 – 68. 120 (60 % male.	10, 5 – 14 All 10, 8 – 17 Surv 10, 4 – 14 non surv	44 (22.1 %) died	open-label, individually randomized, controlled trial
Fan et al., 2020 Pre-print	Wuhan China	30DEC2019 to 16FEB2020	101 patients, mean age 65.5 years (range 24 to 83). 64 males, 37 females. All died. Majority underlying, 25.7 % two conditions.	47 of 101 direct to ICU: 8, 4 to 11.	All died	57 patients lab confirmed, 44 clinically consistent, all died
Singapore						
Young et al., 2020 Case series	Singaore	To 25FEB2020	2 of 18 admitted to ICU. Median age was 47 yrs, 50 % male, 50 % female	Mean 6 (range 5 – 7)		
Italy						
Graselli et al. 2020b PR	Lombardy Italy	20FEB2020 to 18MAR2020	1,591 patients admitted to ICU, with 1,581 ICU info available	9, 6 – 13; All 10, 8 – 14; continuing care n = 920 8 , 5 – 12; discharged n = 256 7, 5 – 11; died n = 405	ICU mortality 26 %. 64 + yrs (n = 786) 36 % died 63 or younger (n = 795) 15 % died. At study cut off: 405 of 1,581 (26 %) died in ICU 256 of 1,591 (16 %) discharged 920 of 1,591 (58 %) continued in ICU.	ICU patients only; incluson criterion
COVID-19 Surveillance Group, 2020 Health report	Italy	Up to 29APR2020	25,452 deceased patients. Median age was 81 years (IQR 73 to 87). Females 9,684 (38 %). Overall, 3.8 % presented with a no pre-existing condition, 14.5 % with 1, 21.4 % with 2, and 60.3 % with 3 or more. Number of patients transferred to ICU not reported.	8 (if included ICU care; IQR or range not presented).	All patients died. ARDS in 97.1 % of cases,acutre renal failure in 23,3 %. Superinfection 12.6 % and acute caridac injury in 10.9 % of cases.	All patients died; inclusion criterion It is not clear what number of patients were transferred to ICU care.
Switzerland						
Ceruti et al., 2020	Switzerland	14MAR2020 to 12APR2020	41 ICU patients. mean age 64 (/-16.5) years, 35 (85 %) male.	9, 4 – 12.5; discharged	10 died (24 %); 2 transferred out; 24 (61 %) discharge	41 patients addmitted to ICU from 310 at clinic. 34 (83 %) required mechanical ventilaton. 25 (61 %) to discharge. Median duration of MV 7, 3 – 10 d.
UK						
ICNARC, 2020a 08MAY2020	UK	Up to 08MAY2020	8,250 Patients. Age 60, 51 – 67. 5,879 (72%) Male. 5,580 of 7,594 (73 %) patients had BMI ≥ 25.	ICU: 8, 3 – 17; Surv n = 3,271 8, 4 – 14; Non surv, n = 2,872	6,143 of 8,250 completed ICU care: 3,271 of 6,143 (55 %) alive	4,861 of 8,250 (64% mechanical vent within 24 hrs APACHE II score 14,

				1, 0 to 3 Pre ICU LOS, n = 7,524	2,872 of 6,143 (47 %) died	11 – 18; n = 7,835
USA						
Kujawski et al., 2020	USA 6 States 6 of 12 CA	20JAN2020 to 05FEB2020	12 patients. Median age 53 yrs (range 21 to 68). 8 male. 4 of 5 with underlying conditions hospitalised	5	11 of 12 discharged or remained home isolation 1 remianed hospitalized at study cut off (patient who was admitted to ICU)	Case series n = 12.
Bhatraju et la., 2020 Case Series	Seattle, USA	24FEB2020 to 09MAR2020	24 Patients. Mean age 64 ± 18 yrs, 63 % male	9, 4 to 14 All ICU 14, 4 – 17 Surv only		All ICU, inclusion criterion 12 of 24 died Surv only: 5 dischaged home 4 discharged to general wards 3 remained on mechanical ventilation
Cummings et al., 2020	US, New Yord	02MAR2020 to 01APR2020	257 of 1,150 hospitalised patients categorised critical. Meidan age 62, 51 – 72. 170 of 257 ((66 %) male. 82 % at least one pre-existing condition.	8, 5 – 12 (died only)	86 of 257 (33 %) died in hospital. 122 of 257 continuing care. 4 transferred. 45 of 257 discharged alive.	201 of 257 received invasive mechanical ventilation. 13, 9 – 17 d.
Petrilli et al., 2020	New York USA	01MAR2020 to 02APR2020	4,102 hospitalised patients . mean 52 yers (36 – 65). 2072 (50.5 %) male. 1,999 hospitalised, 650 critical, 116 died or hopsice, 534 to ICU.	6, 3 – 9 (discharge or died) 11.4, 8.4 – 15.4 (continuing care)	Of 534 to ICU, 176 died or to hospice, 49 discharged, 309 continuing care	1,999 of 4,103 positive were hospitalised.
Argentziano et al., 2020	New York USA	01MAR2020 to 05APR2020	1000 patients. 150 ED only treatment, 614 admitted to general wards, 236 to ICU. Median age (all) 63, 50 75. 596 (60 %) male. Only 82 (8.2 %) no pre-existing conditions. 75 % BMI > 25.2. Median age (ICU n = 236) 62, 52 – 72. 158 of 236 (67 %) male. 75 % BMI > 25.7.	23, 12 – 32 includes ICU	At cutoff 87 (37 %) continuing care 46 (20 %) discharged; 103 (44 %) ICU cases died	Of the 150 ED only patients; 85 % discharged, 14.7 % died before admission.
Badawi et al., 2020	USA New York City	23MAR2020 to 06APR2020	Data relates to 465 patients. Mean age 63.7 (SD +/- 14.3). 312 (67 %) male.	3.8, 1.4 – 7.3 4.2, 1.8 – 7.7 (Mechanically ventilated		Study examined ICU occupancy. During pandemic - DRS highest reached 37.5 (1.5 – 71.5) versus (0.9 (0.2 to 7.1; pre pandemic. Last DRS before ICU discharge: 17.5 (0.8 – 71) vs 0.3 (0.1 – 1.2 pre-pandemic.
Lewnard et al., 2020	USA California and Washington state	To 09APR2020	1,277 patients. Median age 60, 47 – 72. 56.8 % male. 817 of 1,299 (64 %) completed stay. 158 of 617 (25.6 %) admitted to ICU (data not available from Washington State)	Mean, IQR 8.1, 3.9 – 11.2	Estimates of admissons to ICU 41.9 % (34.1 – 51.4 %) Esimtates for ICU fatalities 17.8 % (14.3 – 22.2 %)	Adjusted for censored data hence estimates calculated.
Mexico						
Valente Acosta et al., 2020	Mexico City	13MAR2020 to 13APR2020	33 patients. Mean age 60.6 ± 12.7 years, 23 (70 %) male. 23 (70 %) overwieght or obese.	7.5, 4.25–8.75 Severe n= 20 23, 16–24.75 Critical n = 4	All survived to study cutoff. 20 of 28 severe discharged; 4 of 8 critical discharged	91 % swab positive. All admitted to ICU

890 Table 4. A summary of published articles and reports relating to length of hospital stay prior to transfer to ICU following COVID-19 infection, by country.

Paper	Location	Timing	Demographics	Pre-ICU; LOS median (days), IQR	Outcomes	Comments
China						
Fan et al., 2020 Pre-print	Wuhan China	30DEC2019 to 16FEB2020	101 patients, mean age 65.5 years (range 24 to 83). 64 males, 37 females. All died. Majority with underlying conditions, 25.7 % with two underlying conditions.	47 of 101 direct to ICU:54 transferred to ICU with aggravating conditions 8, 4 to 11.	All died – criteria for inclusion was death	Early paper - 57 patients lab confirmed, 44 clinically consistent
Singapore						
Young et al., 2020 Case series	Singaore	To 25FEB2020	18 patients. Median age was 47 yrs, 50 % male, 50 % female	Mean 6 (range 5 – 7)	No deaths	2 pateints ICU Main presentation mild respiratory infection
UK						
ICNARC, 2020a 08MAY2020	UK	Up to 08MAY2020	8,250 Patients. Age 60, 51 – 67. 5,879 (72%) Male. 5,580 of 7,594 (73 %) patients had BMI ≥ 25.	1, 0 to 3 Pre ICU LOS, n = 8,233	6,143 of 8,250 completed ICU care: 3,271 of 6,143 (55 %) alive 2,872 of 6,143 (47 %) died	4,861 of 8,250 (64% mech vent within 24 hrs APACHE II score 14, 11 – 18; n = 7,835
USA						
Kujawski et al., 2020	USA 6 States	20JAN2020 to 05FEB2020	12 patients. Median age 53 yrs (range 21 to 68). 8 male. 4 of 5 with one or more underlying conditions hospitalised	5 days	11 of 12 discharged or remained home isolation 1 remianed hospitalized at study cut off (ICU)	1 patient ICU Hospitalised patients worsened clinically in second week.